AQP4+ NMOSD

Clinical trials for AQP4+ NMOSD explained in plain language.

Never miss a new study

Get alerted when new AQP4+ NMOSD trials appear

Sign up with your email to follow new studies for AQP4+ NMOSD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New registry to monitor Real-World impact of C5 inhibitors in rare neurological disease

Knowledge-focused Recruiting now

This study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs (eculizumab or ravulizumab) to prevent relapses. Researchers will collect data on relapse rates, safety, and quality of life o…

Matched conditions: AQP4+ NMOSD

Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused

Last updated May 15, 2026 11:57 UTC

AQP4+ NMOSD

Get alerted when new AQP4+ NMOSD trials appear

New registry to monitor Real-World impact of C5 inhibitors in rare neurological disease